microRNA Expression Profile in Patients with Stage II Colorectal Cancer: A Turkish Referral Center Study

  • Tanoglu, Alpaslan (Gastroenterology Department, GATA Haydarpasa Training Hospital) ;
  • Balta, Ahmet Ziya (General Surgery Department, GATA Haydarpasa Training Hospital) ;
  • Berber, Ufuk (Pathology Department, GATA Haydarpasa Training Hospital) ;
  • Ozdemir, Yavuz (Gastroenterology Department, GATA Haydarpasa Training Hospital) ;
  • Emirzeoglu, Levent (General Surgery Department, GATA Haydarpasa Training Hospital) ;
  • Sayilir, Abdurrahim (Gastroenterology Department, Giresun State Hospital) ;
  • Sucullu, Ilker (General Surgery Department, GATA Haydarpasa Training Hospital)
  • Published : 2015.03.18


Background: There are increasing data about microRNAs (miRNA) in the literature, providing abundant evidence that they play important roles in pathogenesis and development of colorectal cancer. In this study, we aimed to investigate the miRNA expression profiles in surgically resected specimens of patients with recurrent and non-recurrent colorectal cancer. Materials and Methods: The study population included 40 patients with stage II colorectal cancer (20 patients with recurrent tumors, and 20 sex and age matched patients without recurrence), who underwent curative colectomy between 2004 and 2011 without adjuvant therapy. Expression of 16 miRNAs (miRNA-9, 21, 30d, 31, 106a, 127, 133a, 133b, 135b, 143, 145, 155, 182, 200a, 200c, 362) was verified by quantitative real-time polymerase chain reaction (qRT-PCR) in all resected colon cancer tissue samples and in corresponding normal colonic tissues. Data analyses were carried out using SPSS 15 software. Values were statistically significantly changed in 40 cancer tissues when compared to the corresponding 40 normal colonic tissues (p<0.001). MiR-30d, miR-133a, miR-143, miR-145 and miR-362 expression was statistically significantly downregulated in 40 resected colorectal cancer tissue samples (p<0.001). When we compared subgroups, miRNA expression profiles of 20 recurrent cancer tissues were similar to all 40 cancer tissues. However in 20 non-recurrent cancer tissues, miR-133a expression was not significantly downregulated, moreover miR-133b expression was significantly upregulated (p<0.05). Conclusions: Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior.


Colorectal cancer;microRNA expression profiling;cancer recurrence


  1. Aghanoori MR, Mirzaei B, Tavallaei M (2014). MiRNA molecular profiles in human medical conditions: connecting lung cancer and lung development phenomena. Asian Pac J Cancer Prev, 15, 9557-65.
  2. Ahmed FE (2007). Role of miRNA in carcinogenesis and biomarker selection: a methodological view. Expert Rev Mol Diagn, 7, 569-603.
  3. Bauer KM, Hummon AB (2012). Effects of the miR-143/- 145 microRNA cluster on the colon cancer proteome and transcriptome. J Proteome Res, 11, 4744-54.
  4. Bentwich I, Avniel A, Karov Y, et al (2005). Identification of hundreds of conserved and nonconserved human microRNAs. Nat Gen, 37, 766-770.
  5. Berber U, Yilmaz I, Narli G et al (2014). miR-205 and miR- 200c: Predictive Micro RNAs for Lymph Node Metastasis in Triple Negative Breast Cancer. J Breast Cancer, 17, 143-8.
  6. Bozkurt O, Inanc M, Turkmen E, et al (2014). Clinicopathological characteristics and prognosis of patients according to recurrence time after curative resection for colorectal cancer. Asian Pac J Cancer Prev, 15, 9277-81.
  7. Calin GA, Croce CM (2006). MicroRNA signatures in human cancers. Nat Rev Cancer, 6, 857-66.
  8. Carthew RW, Sontheimer EJ (2009). Origins and mechanisms of miRNAs and siRNAs. Cell, 136, 642-655.
  9. Christensen LL, Tobiasen H, Holm A, et al (2013). MiRNA-362- 3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer. Int J Cancer, 133, 67-78.
  10. Della Vittoria Scarpati G, Calura E, Di Marino M et al (2014). Analysis of differantial miRNA expression in primary tumor and stroma of colorectal cancer patients. Biomed Res Int, 2014, 840921.
  11. Diaz R, Silva J, Garcia JM, et al (2008). Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer, 47, 794-802.
  12. Farh KK, Grimson A, Jan C, et al (2005). The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science, 310, 1817-21.
  13. Farooqi AA, Qureshi MZ, Coskunpinar E et al (2014). MiR-421, miR-155 and miR-650: emerging trends of regulation of cancer and apoptosis. Asian Pac J Cancer Prev, 15, 1909-12.
  14. Fritzmann J, Morkel M, Besser D, et al (2009). A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. Gastroenterol, 137, 165-75.
  15. Huang Z, Huang D, Ni S, et al (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 127, 118-26.
  16. Karaayvaz M, Pal T, Song B, et al (2011). Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer, 10, 340-7.
  17. Kulda V, Pesta M, Topolcan O, et al (2010). Relevance of miR- 21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cytogenet, 200, 154-160.
  18. Link A, Balaguer F, Shen Y et al (2010). Fecal microRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev, 19, 1766-74.
  19. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real time qantitative PCR and the 2-${\Delta}{\Delta}CT$ method. Methods, 25, 402-8.
  20. Ma ZB, Kong XL, Cui G, et al (2014). Expression and clinical significance of miRNA-34a in colorectal cancer. Asian Pac J Cancer Prev, 15, 9265-70.
  21. Mo ZH, Wu XD, Li S, Fei BY, Zhang B. Expression and clinical significance of microRNA-376a in colorectal cancer. Asian Pac J Cancer Prev, 15, 9523-7.
  22. Nakajima G, Hayashi K, Xi Y, et al (2006). Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics, 3, 317-24.
  23. Omranipour R, Mahmoodzadeh H, Safavi F (2014). Prevalence of local recurrence of colorectal cancer at the Iranian Cancer Institute. Asian Pac J Cancer Prev, 15, 8587-9.
  24. Rosenfeld N, Aharonov R, Meiri E, et al (2008). MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol, 26, 462-9.
  25. Schepeler T, Reinert JT, Ostenfeld MS, et al (2008). Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res, 68, 6416-24.
  26. Slaby O, Svoboda M, Fabian P, et al (2007). Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinico-pathologic features of colorectal cancer. Oncology, 72, 397-402.
  27. Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al (2012). Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet, 380, 1840-50.
  28. Su SF, Chang YW, Andreu-Vieyra C, et al (2013). miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene, 32, 4694-701.
  29. Xi Y, Formentini A, Chien M, et al (2006). Prognostic values of microRNAs in colorectal cancer. Biomark Insights, 2, 113-21.
  30. Wang LL, Du LT, Li J, et al (2014). Decreased expression of miR-133a correlates with poor prognosis in colorectal cancer patients. World J Gastroenterol, 20, 11340-6.
  31. Wu WK, Law PT, Lee CW, et al (2011). MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis, 32, 247-53.
  32. Zhang W, Winder T, Ning Y, et al (2011). A let-7 microRNAbinding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol, 22, 104-9.
  33. Zhang GJ, Xiao HX, Tian HP, et al (2013). Upregulation of microRNA-155 promotes the migration and invasion of colorectal cancer cells through the regulation of claudin-1 expression. Int J Mol Med, 31, 1375-80.

Cited by

  1. Colorectal adenoma and carcinoma specific miRNA profiles in biopsy and their expression in plasma specimens vol.9, pp.1, 2017,
  2. MiR-362-3p functions as a tumor suppressor through targeting MCM5 in cervical adenocarcinoma vol.38, pp.3, 2018,